2Bando M, Hosono T, Mato N et al. Long-term effieary inhaled N- acelylcysteine patients with idoopathic pulmonary fibrosis [ J ]. In- tern Med ,2010,49 (21) :2289 - 2296.
3Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ ALAT statement : idiopathic pulmonary fibrosis : evidence-based guidelines for diagnosis and management [ J ]. Am J Respir Crit Care Med ,2011 ;183 : 788 -824.
4Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone Clinical Study Group in Japan. Pirfenidone in Idiopathic Pulmonary Fibrosis: A phase III clinical trial in Japan [ J]. Eur Respir,2010;35:821 - 829.
5Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis ( CAPACITY ) : two randomised trials[ J]. Lancet, 2011 ;377:1760 - 1769.
6Taniguchi H,Ebina M, Kondoh et al. Pirfenidone in idiopathic pul- monary fibrosis [ J ]. Eur Respir 2010,35 ( 4 ) : 821 - 829.
7Luca Richeldi, Ulrich Costabel, Moises Selman, et al. Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis [ J ]. The New England Journal of Medicine,2011,365 (12) : 1079 - 1087.
8Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis [ J ]. N Engl J Med, 2014,370:2071 - 2082.
9Choe JY, Jung H J, Park KY, et. al. Antifibrotic effect ofthalidomide throuh inhibiting TGF-βinduced ERK1/2 pathways in bleomycin induced lung fibros is in mice [ J ]. Inf lamm Res, 2010,59 ( 3 ) : 177.
10MR Horton, Santopietro V. Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis [ J]. Ann Intern Med,2012,157 : 398 - 4O6.
